MENU

Medical Developments Ltd International Ltd facing a world of pain in the U.S.

Shares in Medical Developments Ltd International Ltd (ASX: MVP) tumbled 19% to $4.71 today after the group warned that “the clinical program for Penthrox to be approved for sale in the USA is to be put on hold pending a letter outlining outstanding issues and concerns.”

The contents of the letter from the U.S. healthcare regulator the FDA will be crucial in determining whether or not Penthrox has a shot at gaining regulatory approval in the U.S.

Medical Developments International is the company behind the production and distribution of Penthrox or the ‘green whistle’ emergency pain medical-whistle-like-device that patients inhale as an analgesic in order to treat pain.

It’s commonly carried and used by accident and emergency response teams, or other medical professionals who may need to treat sudden patient pain in athletes for example.

The ‘green whistle’ has been approved for use in Australia, the Middle East and more recently across most of the Western European nations, with just the Holy Grail of the lucrative U.S. healthcare market seemingly between it and unambiguous success.

It seems the champagne is on ice for Medical Developments investors, who’ll hope it’s not needed as an analgesic in the event of a painful rejection by the FDA.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Atlassian.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.